Echosens releases white paper for NAFLD awareness, diagnostics

Echosens announced the release of a white paper on nonalcoholic fatty liver disease that provides details on risk factors affecting U.S. patients along with solutions for early detection to improve awareness of the increasingly prevalent disease, according to a press release.

“In this white paper, our team illustrates the importance for greater public awareness and education surrounding NAFLD and the importance of early detection,” Laurent Sandrin, founder of Echosens, said in the release. “Authors also stress the role of physicians, especially primary care doctors, in adopting non-invasive assessment tools that can be utilized to measure liver stiffness and fat during annual physical exams. With earlier detection, lifestyle changes can be implemented to prevent disease progression and avoid serious conditions such as cirrhosis or liver cancer.”

In the white paper, “The Looming Epidemic: Non-Alcoholic Fatty Liver Disease (NAFLD),” the authors explain the efficacy of the Echosens’ Fibroscan for early detection of NAFLD.

“While the presence of some fat in the liver is normal, when fat accounts for more than five percent of the organ’s weight, it becomes dangerous,” Sandrin concluded in the release. “As a reliable tool in the front-line battle against the liver disease epidemic, FibroScan is a game-changer.”

Reference: www.echosens.com